Intratumoral Heterogeneity: More Than Just Mutations

Published on Jul 1, 2019in Trends in Cell Biology16.041
· DOI :10.1016/J.TCB.2019.03.003
Kunihiko Hinohara20
Estimated H-index: 20
(Harvard University),
Kornelia Polyak108
Estimated H-index: 108
(Harvard University)
Sources
Abstract
Most human tumors are composed of genetically and phenotypically heterogeneous cancer cell populations, which poses a major challenge for the clinical management of cancer patients. Advances of single-cell technologies have allowed the profiling of tumors at unprecedented depth, which, in combination with newly developed computational tools, enable the dissection of tumor evolution with increasing precision. However, our understanding of mechanisms that regulate intratumoral heterogeneity and our ability to modulate it has been lagging behind. Recent data demonstrate that epigenetic regulators, including histone demethylases, may control the cell-to-cell variability of transcriptomes and chromatin profiles and they may modulate therapeutic responses via this function. Thus, the therapeutic targeting of epigenetic enzymes may be used to decrease intratumoral cellular heterogeneity and treatment resistance, when used in combination with other types of agents.
📖 Papers frequently viewed together
201441.84Science
27 Authors (Jianjun Zhang, ..., Andrew Futreal)
645 Citations
5,512 Citations
31.7k Citations
References93
Newest
#1Joshua L. Payne (ETH Zurich)H-Index: 19
#2Andreas Wagner (UZH: University of Zurich)H-Index: 73
Evolvability is the ability of a biological system to produce phenotypic variation that is both heritable and adaptive. It has long been the subject of anecdotal observations and theoretical work. In recent years, however, the molecular causes of evolvability have been an increasing focus of experimental work. Here, we review recent experimental progress in areas as different as the evolution of drug resistance in cancer cells and the rewiring of transcriptional regulation circuits in vertebrate...
101 CitationsSource
#1Kunihiko Hinohara (Harvard University)H-Index: 20
#2Hua-Jun Wu (Harvard University)H-Index: 17
Last. Kornelia PolyakH-Index: 108
view all 28 authors...
Summary Members of the KDM5 histone H3 lysine 4 demethylase family are associated with therapeutic resistance, including endocrine resistance in breast cancer, but the underlying mechanism is poorly defined. Here we show that genetic deletion of KDM5A/B or inhibition of KDM5 activity increases sensitivity to anti-estrogens by modulating estrogen receptor (ER) signaling and by decreasing cellular transcriptomic heterogeneity. Higher KDM5B expression levels are associated with higher transcriptomi...
91 CitationsSource
#1Amanda Balboni Iniguez (Broad Institute)H-Index: 8
#2Gabriela Alexe (Broad Institute)H-Index: 38
Last. Kimberly Stegmaier (Broad Institute)H-Index: 45
view all 26 authors...
Summary Drug resistance represents a major challenge to achieving durable responses to cancer therapeutics. Resistance mechanisms to epigenetically targeted drugs remain largely unexplored. We used bromodomain and extra-terminal domain (BET) inhibition in neuroblastoma as a prototype to model resistance to chromatin modulatory therapeutics. Genome-scale, pooled lentiviral open reading frame (ORF) and CRISPR knockout rescue screens nominated the phosphatidylinositol 3-kinase (PI3K) pathway as pro...
28 CitationsSource
#1Robert J. Kimmerling (MIT: Massachusetts Institute of Technology)H-Index: 10
#2Sanjay PrakadanH-Index: 4
Last. Scott R. Manalis (MIT: Massachusetts Institute of Technology)H-Index: 50
view all 13 authors...
Mass and growth rate are highly integrative measures of cell physiology not discernable via genomic measurements. Here, we introduce a microfluidic platform enabling direct measurement of single-cell mass and growth rate upstream of highly multiplexed single-cell profiling such as single-cell RNA sequencing. We resolve transcriptional signatures associated with single-cell mass and growth rate in L1210 and FL5.12 cell lines and activated CD8+ T cells. Further, we demonstrate a framework using th...
38 CitationsSource
#1Devon A. Lawson (UCI: University of California, Irvine)H-Index: 22
#2Kai Kessenbrock (UCI: University of California, Irvine)H-Index: 22
Last. Zena Werb (UCSF: University of California, San Francisco)H-Index: 179
view all 5 authors...
Tumours comprise a heterogeneous collection of cells with distinct genetic and phenotypic properties that can differentially promote progression, metastasis and drug resistance. Emerging single-cell technologies provide a new opportunity to profile individual cells within tumours and investigate what roles they play in these processes. This Review discusses key technological considerations for single-cell studies in cancer, new findings using single-cell technologies and critical open questions ...
186 CitationsSource
#1Xun Huang (CAS: Chinese Academy of Sciences)H-Index: 12
#2Juan Yan (CAS: Chinese Academy of Sciences)H-Index: 7
Last. Meiyu Geng (CAS: Chinese Academy of Sciences)H-Index: 38
view all 19 authors...
Summary Mutations or aberrant upregulation of EZH2 occur frequently in human cancers, yet clinical benefits of EZH2 inhibitor (EZH2i) remain unsatisfactory and limited to certain hematological malignancies. We profile global posttranslational histone modification changes across a large panel of cancer cell lines with various sensitivities to EZH2i. We report here oncogenic transcriptional reprogramming mediated by MLL1's interaction with the p300/CBP complex, which directs H3K27me loss to recipr...
66 CitationsSource
#1Tyler Risom (OHSU: Oregon Health & Science University)H-Index: 8
#2Ellen M. Langer (OHSU: Oregon Health & Science University)H-Index: 5
Last. Rosalie C. Sears (OHSU: Oregon Health & Science University)H-Index: 44
view all 21 authors...
Intratumoral heterogeneity in cancers arises from genomic instability and epigenomic plasticity and is associated with resistance to cytotoxic and targeted therapies. We show here that cell-state heterogeneity, defined by differentiation-state marker expression, is high in triple-negative and basal-like breast cancer subtypes, and that drug tolerant persister (DTP) cell populations with altered marker expression emerge during treatment with a wide range of pathway-targeted therapeutic compounds....
61 CitationsSource
#1Leeat Keren (Stanford University)H-Index: 14
#2Marc Bosse (Stanford University)H-Index: 3
Last. Michael Angelo (Stanford University)H-Index: 16
view all 12 authors...
The immune system is critical in modulating cancer progression, but knowledge of immune composition, phenotype, and interactions with tumor is limited. We used multiplexed ion beam imaging by time-of-flight (MIBI-TOF) to simultaneously quantify in situ expression of 36 proteins covering identity, function, and immune regulation at sub-cellular resolution in 41 triple-negative breast cancer patients. Multi-step processing, including deep-learning-based segmentation, revealed variability in the co...
293 CitationsSource
#1Andrew C. Nelson (UMN: University of Minnesota)H-Index: 14
#2Heather L. Machado (Tulane University)H-Index: 8
Last. Kathryn L. Schwertfeger (UMN: University of Minnesota)H-Index: 27
view all 3 authors...
Refinements in early detection, surgical and radiation therapy, and hormone receptor-targeted treatments have improved the survival rates for breast cancer patients. However, the ability to reliably identify which non-invasive lesions and localized tumors have the ability to progress and/or metastasize remains a major unmet need in the field. The current diagnostic and therapeutic strategies focus on intrinsic alterations within carcinoma cells that are closely associated with proliferation. How...
29 CitationsSource
#1Charissa Kim (University of Texas MD Anderson Cancer Center)H-Index: 7
#2Ruli Gao (University of Texas MD Anderson Cancer Center)H-Index: 13
Last. Nicholas Navin (University of Texas MD Anderson Cancer Center)H-Index: 37
view all 9 authors...
Summary Triple-negative breast cancer (TNBC) is an aggressive subtype that frequently develops resistance to chemotherapy. An unresolved question is whether resistance is caused by the selection of rare pre-existing clones or alternatively through the acquisition of new genomic aberrations. To investigate this question, we applied single-cell DNA and RNA sequencing in addition to bulk exome sequencing to profile longitudinal samples from 20 TNBC patients during neoadjuvant chemotherapy (NAC). De...
340 CitationsSource
Cited By76
Newest
Abstract null null Iron oxide (Fe3O4) magnetic nanoparticles (MNs) delivered to the tumor under the influence of magnetic fields can generate reactive oxygen species (ROS) that affect the activity of mitochondrial enzymes, DNA damage and abnormal cell growth. Previous investigations used rotating magnetic fields to inhibit tumor growth. Herein, we question whether the magneto-mechanical effects of MNs under an inhomogeneous stationary magnetic field (ISMF) can modulate tumor heterogeneity, ROS a...
Source
#1A. I. Stukan (Kuban State Medical University)
#2A. Y. Goryainova (Kuban State Medical University)
view all 5 authors...
Source
#1Chang Gong (Johns Hopkins University)H-Index: 11
#2Alvaro Ruiz-Martinez (Johns Hopkins University)
Last. Aleksander S. Popel (Johns Hopkins University)H-Index: 78
view all 4 authors...
Quantitative systems pharmacology (QSP) models have become increasingly common in fundamental mechanistic studies and drug discovery in both academic and industrial environments. With imaging techniques widely adopted and other spatial quantification of tumor such as spatial transcriptomics gaining traction, it is crucial that these data reflecting tumor spatial heterogeneity be utilized to inform the QSP models to enhance their predictive power. We developed a hybrid computational model platfor...
Source
#1Tugba Keskin (CHUV: University Hospital of Lausanne)H-Index: 2
#2Beatrice Rucci (CHUV: University Hospital of Lausanne)
Last. Stefano La Rosa (CHUV: University Hospital of Lausanne)H-Index: 38
view all 17 authors...
Targeting of the most aggressive tumor cell subpopulations is key for effective management of most solid malignancies. However, the metastable nature of tumor heterogeneity, which allows cells to transition between strong and weak tumorigenic phenotypes, and the lack of reliable markers of tumor-promoting properties hamper identification of the most relevant cells. To overcome these obstacles, we designed a functional microRNA (miR)–based live-cell reporter assay to identify highly tumorigenic c...
Source
#1Matthew L. Tan (Cornell University)
#2Lu Ling (Cornell University)H-Index: 4
Last. Claudia Fischbach (Cornell University)H-Index: 43
view all 3 authors...
Despite decades of research and advancements in diagnostic and treatment modalities, cancer remains a major global healthcare challenge. This is due in part to a lack of model systems that allow investigating the mechanisms underlying tumor development, progression, and therapy resistance under relevant conditions in vitro. Tumor cell interactions with their surroundings influence all stages of tumorigenesis and are shaped by both biological and biophysical cues including cell-cell and cell-extr...
Source
#1Weiyi Jiang (SDUTCM: Shandong University of Traditional Chinese Medicine)
#2Tingting Xia (SDUTCM: Shandong University of Traditional Chinese Medicine)
Last. Changgang Sun (SDUTCM: Shandong University of Traditional Chinese Medicine)H-Index: 7
view all 6 authors...
Epigenetics, including DNA methylation, histone modification, and noncoding RNA regulation, are physiological regulatory changes that affect gene expression without modifying the DNA sequence. Although epigenetic disorders are considered a sign of cell carcinogenesis and malignant events that affect tumor progression and drug resistance, in view of the reversible nature of epigenetic modifications, clinicians believe that associated mechanisms can be a key target for cancer prevention and treatm...
Source
BRAFV600E melanoma patients, despite initially responding to the clinically prescribed anti-BRAFV600E therapy, often relapse, and their tumors develop drug resistance. While it is widely accepted that these tumors are originally driven by the BRAFV600E mutation, they often eventually diverge and become supported by various signaling networks. Therefore, patient-specific altered signaling signatures should be deciphered and treated individually. In this study, we design individualized melanoma co...
Source
#1Spear Js (ND: University of Notre Dame)
#2Katharine A. White (ND: University of Notre Dame)H-Index: 9
Transient changes in intracellular pH (pHi) have been shown to regulate normal cell behaviors like migration and cell-cycle progression, while dysregulated pHi dynamics are a hallmark of cancer. However, little is known about how pHi heterogeneity and dynamics influence population-level measurements or single-cell behaviors. Here, we present and characterize single-cell pHi heterogeneity distributions in both normal and cancer cells and measure dynamic pHi increases in single cells in response t...
Source
#1Yvonne L. Chao (UNC: University of North Carolina at Chapel Hill)H-Index: 4
#2Chad V. PecotH-Index: 30
The epigenetic landscape, which in part includes DNA methylation, chromatin organization, histone modifications, and noncoding RNA regulation, greatly contributes to the heterogeneity that makes developing effective therapies for lung cancer challenging. This review will provide an overview of the epigenetic alterations that have been implicated in all aspects of cancer pathogenesis and progression as well as summarize clinical applications for targeting epigenetics in the treatment of lung canc...
1 CitationsSource
#1Corey E. Hayford (Vandy: Vanderbilt University)H-Index: 2
#2Darren R. Tyson (Vandy: Vanderbilt University)H-Index: 23
Last. Leonard A. Harris (UA: University of Arkansas)H-Index: 15
view all 6 authors...
Tumor heterogeneity is a primary cause of treatment failure and acquired resistance in cancer patients. Even in cancers driven by a single mutated oncogene, variability in response to targeted therapies is well known. The existence of additional genomic alterations among tumor cells can only partially explain this variability. As such, nongenetic factors are increasingly seen as critical contributors to tumor relapse and acquired resistance in cancer. Here, we show that both genetic and nongenet...
Source